Wide Ranks

GYRE

Gyre Therapeutics, Inc.

11.70

Top Statistics
Market Cap 1 B Forward PE 25.43 Revenue Growth -14.00 %
Current Ratio 3.44 Trailing PE 0.0000 Earnings Growth -70.50 %
Profit Margins -77.04 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 62.22 Enterprise / Revenue 11.20 Price To Sales Trailing12 Months 9.00
Profitability
Profit Margins -77.04 % Operating Margins 12.93 %
Balance Sheet
Total Cash 25 M Total Cash Per Share 0.2930 Total Debt 1 M
Total Debt To Equity 2.10 Current Ratio 3.44 Book Value Per Share -0.2070
All Measures
Short Ratio 1166.00 % Message Board Id finmb_100542295 Shares Short Prior Month 457298
Return On Equity -0.8274 City San Diego Uuid fcf12068-c88b-34d0-8632-7e45e01ea8d2
Previous Close 12.09 First Trade Date Epoch Utc 1 B Book Value -0.2070
Total Debt 1 M Volume 78894 Last Split Date 1 B
Fifty Two Week Low 8.26 Total Cash Per Share 0.2930 Total Revenue 111 M
Shares Short Previous Month Date 1 B Audit Risk 9 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins 12.93 % Last Dividend Value 3.60
Net Income To Common -85970000 Short Percent Of Float 0.0263 Implied Shares Outstanding 85 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 78300
Average Volume10days 78300 Total Cash 25 M Next Fiscal Year End 1 B
Revenue Per Share 1.46 Held Percent Insiders 0.7470 Ebitda Margins 18.00 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 7 Regular Market Previous Close 12.09 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 13.59 Open 12.40
Free Cashflow 8 M State CA Dividend Yield 0.00 %
Return On Assets 0.1018 Time Zone Short Name EST Board Risk 10
Trailing Eps -1.04 Day Low 11.51 Address1 12770 High Bluff Drive
Shares Outstanding 85 M Compensation Risk 9 Price Hint 2
Target High Price 0.0000 Website https://www.gyretx.com 52 Week Change -0.5026
Average Volume 57920 Earnings Quarterly Growth 90.40 % Forward Eps 0.4600
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 287.10 %
Last Split Factor 1:15 Regular Market Day High 12.55 Is_sp_500 False
Profit Margins -77.04 % Debt To Equity 2.10 Fifty Two Week High 30.40
Day High 12.55 Shares Short 376581 Regular Market Open 12.40
Industry Key biotechnology Earnings Growth -70.50 % Enterprise To Revenue 11.20
Revenue Growth -14.00 % Shares Percent Shares Out 0.0040 Operating Cashflow 8 M
Currency USD Time Zone Full Name America/New_York Market Cap 1 B
Is_nasdaq_100 False Zip 92130 Quote Type EQUITY
Industry Biotechnology Long Name Gyre Therapeutics, Inc. Overall Risk 9
Regular Market Day Low 11.51 Held Percent Institutions 0.0150 Current Price 11.70
Address2 Suite 150 Enterprise To Ebitda 62.22 Financial Currency USD
Current Ratio 3.44 Gross Margins 96.25 % Industry Disp Biotechnology
Country United States Float Shares 15 M Two Hundred Day Average 14.16
Governance Epoch Date 1 B Enterprise Value 1 B Price To Sales Trailing12 Months 9.00
Forward PE 25.43 Regular Market Volume 78894 Last Dividend Date 1 B
Ebitda 20 M Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.

It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.

The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.

In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension.

The company was founded in 2002 and is headquartered in San Diego, California.

Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.